摘要
目的观察奥施康定联合唑来膦酸治疗晚期乳腺癌骨转移同期放化疗癌痛的临床效果。方法选取2017年4月～2018年4月冀中能源邢台矿业集团总医院收治的晚期乳腺癌骨转移同期放化疗癌痛患者80例,根据随机数字表法分为对照组和观察组,每组各40例。对照组患者采用奥施康定进行镇痛治疗,观察组患者采用奥施康定联合唑来膦酸进行镇痛治疗。利用疼痛数字评分法(NRS)评估两组患者疼痛程度,利用Karnofsky功能状态评分法(KPS)和肿瘤患者的生存质量评分(QOL)评估两组生存质量,观察两组患者奥施康定用量增减情况及不良反应情况。结果治疗28 d后,两组患者NRS评分低于治疗前,KPS评分、QOL评分高于治疗前,差异有统计学意义(P <0.05)。观察组患者NRS评分低于对照组,KPS评分、QOL评分高于对照组,差异有统计学意义(P <0.05)。观察组患者奥施康定减量率高于对照组,差异有统计学意义(P <0.05)。观察组患者便秘发生率低于对照组,差异有统计学意义(P <0.05)。结论奥施康定联合唑来膦酸治疗晚期乳腺癌骨转移同期放化疗癌痛具有确切的效果,可有效减轻同期放化疗治疗期间的癌痛程度,提高患者生存质量,降低单纯应用奥施康定的不良反应,值得临床推广。
Objective To observe the clinical efficacy of OxyContin combined with Zoledronic Acid in the treatment of advanced breast cancer with bone metastasis cancer pain concurrent with chemoradiation therapy. Methods From April 2017 to April 2018, in Jizhong Energy Xingtai Mining Group General Hospital, 80 patients with advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy were selected, according to random number table method, they were divided into control group and observation group, with 40 cases in each group. Patients in the control group were treated with OxyContin for analgesia, patients in the observation group were treated with OxyContin and Zoledronic Acid for analgesia. The pain level was evaluated by numeric rating scale (NRS), the quality of life of the two groups was evaluated by Karnofsky functional status score (KPS) and the quality of life score (QOL) of the tumor patients, the increase and decrease of OxyContin dosage and adverse reactions in the two groups were observed. Results After 28 days of treatment, the NRS scores of patients in the two groups were lower than before treatment, the KPS score and QOL score were higher than before treatment, the differences were statistically significant (P < 0.05). The NRS scores of patients in the observation group were lower than the control group, the KPS score and QOL score were higher than the control group, the differences were statistically significant (P < 0.05). The rate of OxyContin reduction of patients in the observation group was higher than control group, the difference was statistically significant (P < 0.05). The incidence of constipation of patients in the observation group was lower than control group, the difference was statistically significant (P < 0.05). Conclusion OxyContin combined with Zoledronic Acid has a definite effect in the treatment of advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy. It can effectively reduce the degree of cancer pain, improve the qualit
作者
吴阔
刘孟奇
赵庆书
WU Kuo;LIU Mengqi;ZHAO Qingshu(Department of Radiation Chemotherapy, Jizhong Energy Xingtai Mining Group General Hospital, Hebei Province, Xingtai 054000, China)
出处
《中国医药导报》
CAS
2019年第8期100-103,共4页
China Medical Herald
基金
河北省科学技术厅科学技术成果(20111294)
关键词
奥施康定
唑来膦酸
乳腺癌
骨转移
癌性疼痛
OxyContin
Zoledronic Acid
Breast cancer
Bone metastasis
Cancer pain
